HIP: Study of Hepatitis C Treatment During Pregnancy

Sponsor

Catherine Chappell (Other)

Overall Status

Completed

CT.gov ID

NCT02683005

Collaborator

Gilead Sciences (Industry), University of Nebraska (Other)

Enrollment

Location

Arm

41.1

Actual Duration (Months)

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Sofosbuvir and ledipasvir (LDV/SOF) are new directly acting antiviral drugs for the treatment of hepatitis C (HCV) that are highly effective, orally administered, well tolerated and preclinical evaluations in animal models indicate safe administration during pregnancy. This project will evaluate the safety and pharmacokinetics of antenatal LDV/SOF treatment for 12 weeks during the second and third trimester. If proven to be effective, antenatal treatment of HCV with LDV/SOF will prevent maternal HCV-related liver disease, perinatal transmission of HCV, and community transmission of HCV.

Condition or Disease	Intervention/Treatment	Phase
Hepatitis C Pregnancy	Drug: ledipasvir/sofosbuvir	Phase 1

Detailed Description

There are 3.2 million persons in the United States chronically infected with hepatitis C virus (HCV) with a 1-2.4% prevalence during pregnancy. The recent October 2014 approval of the fixed dose combination, containing the NS5B polymerase inhibitor sofosbuvir (SOF) 90 mg and the NS5A inhibitor ledipasvir (LDV) 400mg, marked a new era of IFN and ribavirin free, directly acting antiviral treatment for HCV. A 12 week treatment course of LDV/SOF resulted in a 99% cure rate when given as a once-a-day oral pill. Based on the animal model data submitted to the FDA, this drug combination was given a pregnancy category B designation, even though there is currently no experience with LDV/SOF in pregnant women.

Pregnancy is a time when women are uniquely motivated to engage in activities which are geared toward improvement of their own health and ensuring the health of their unborn child. As such, pregnant women have frequent prenatal care visits; and health care interventions, such as antiviral therapy and monitoring, can be easily integrated into the existing healthcare infrastructure of prenatal care. The benefits of HCV treatment are numerous, including prevention of severe liver disease, hepatocellular carcinoma, and liver transplantation, as well as improvements physical, emotional and social health. The most recent guidelines by the Infectious Disease Society of America recommend that all HCV-infected persons receive treatment. The antenatal period represents an ideal window of opportunity for treatment of HCV in pregnancy due to increased antenatal health care utilization and prevention of perinatal transmission of HCV to the infant.

Safe administration of drugs in pregnancy may require dose adjustment due to the pregnancy-induced physiologic alternations. Therefore, careful pharmacokinetic (PK) evaluation is a critical first step to ensure safe administration of drugs to both the mother and the developing fetus. This is a single-arm, single-center, open label Phase 1 evaluation of the PK and safety of treating HCV with a 12 week course of LDV/SOF in 15 HCV-infected pregnant women. Therapy will be initiated at approximately 24 weeks of gestation. In this study we will determine: 1) if the PK of the LDV and SOF are similar in pregnancy as compared to those in nonpregnant women, 2) if the viral response to LDV/SOF treatment in pregnancy is similar to that observed in nonpregnant women, and 3) if there are any initial maternal or neonatal safety concerns detected with antenatal LDV/SOF administration compared with HCV-infected historical controls delivered at our institution. From the findings of this study, future studies will seek to optimize the dose, gestational age timing and treatment duration of LDV/SOF during pregnancy. Antenatal HCV treatment will improve maternal health, prevent further HCV transmission in the community and perinatal HCV transmission to the child, and thus enhance the long-term health of two generations.

Study Design

Study Type:

Interventional

Actual Enrollment :

9 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I Pharmacokinetic and Safety Trial of Ledipasvir/Sofosbuvir Fixed Dose Combination in Pregnant Women With Chronic Hepatitis C Virus Infection

Actual Study Start Date :

Sep 1, 2016

Actual Primary Completion Date :

Feb 3, 2020

Actual Study Completion Date :

Feb 3, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Ledipasvir/Sofosbuvir Hepatitis C treatment will be initiated with ledipasvir (400 mg) and sofosbuvir (90mg) fixed dose combination, one pill, once daily for 12 weeks.	Drug: ledipasvir/sofosbuvir Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation. Other Names: Harvoni

Arm

Intervention/Treatment

Experimental: Ledipasvir/Sofosbuvir

Hepatitis C treatment will be initiated with ledipasvir (400 mg) and sofosbuvir (90mg) fixed dose combination, one pill, once daily for 12 weeks.

Drug: ledipasvir/sofosbuvir

Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation.

Other Names:

Harvoni

Outcome Measures

Primary Outcome Measures

Area Under Curve (AUC) Time Frame: predose, 0.5 hr, 1 hr, 2, 3, 4, 5, 8, 12 hrs [3 gestational age time points during the 12 weeks of treatment: 1) Between 25 + 0 and 26 + 5; 2) Between 29 + 0 and 30 + 6; 3) 33 + 0 and 34 + 6 weeks' gestation]
Systemic exposure both LDV and SOF (SOF and inactive metabolite GS-331007) will be assessed at 3 gestational age time points: 1) Late second trimester between 25 + 0 and 26 + 5 weeks' gestation (after at least 10 days of therapy); 2) Early third trimester between 29 + 0 and 30 + 6 weeks' gestation; 3) Late third trimester between 33 + 0 and 34 + 6 weeks' gestation

Secondary Outcome Measures

Sustained viral response at 12 weeks post treatment (SVR 12) [-HCV RNA viral load will be assessed at 12 weeks after completion of LDV/SOF treatment]
An undetectable HCV viral load is considered an SVR 12.
Number of Maternal Adverse Events [-From enrollment to 12 weeks after treatment completion]
Adverse events, including pregnancy and delivery outcomes will be collected prospectively . -
Number of Participants With Abnormal Laboratory Values [-From enrollment to 12 weeks after treatment completion]
Safety laboratories will be sent 4-6 weeks after the initiation of treatment and will include CBC, chemistries, liver function tests, creatinine kinase, lipase, and coagulation studies.
Major Malformations of the Neonate [From birth until 1 year of life]
Major malformations, defined as structural abnormalities with surgical, medical, or cosmetic importance
Length [From birth until 1 year of life]
Length in centimeters will be collected at birth, 1 month, 6 months, and 12 months.
Weight [From birth until 1 year of life]
Weight in kilograms will be collected at birth, 1 month, 6 months, and 12 months.
Head circumference [From birth until 1 year of life]
Head circumference (centimeters) will be collected at birth, 1 month, 6 months and 12 months.
Perninatal Hepatitis C Transmission [From birth until 1 year of life]
Perinatal HCV transmission assessed by presence of hepatitis C virus RNA from infant blood sampling at one month, six months and 12 months.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 39 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Age 18 through 39 years (inclusive) at Screening
Able and willing to provide written informed consent to be screened for and take part in the study procedures
Able and willing to provide adequate locator information
Chronic HCV, genotype 1, 4, 5, 6 infection, defined as HCV antibody detected at least 6 months prior to Screening and detectable HCV RNA viral load at Screening
Desired pregnancy at 23 + 0 to 24 + 6 weeks' gestation at Enrollment with gestational dating confirmed by ultrasound
Singleton gestation with no known fetal abnormalities
Documented negative Hepatitis B testing for current infection (negative HBsAg test) or previous infection (negative anti-HB Core) performed at the screening visit
Negative HIV testing at the screening visit
Per participant report at Screening and Enrollment, agrees not to participate in other research studies involving drugs or medical devices for the duration of study participation

Exclusion Criteria:

Participant report of any of the following at Screening or Enrollment:
Previous treatment for Hepatitis C virus with an NS5A inhibitor or sofosbuvir
Use of any medications contraindicated with concurrent use of ledipasvir or sofobuvir according to the most current HARVONI package insert
Plans to relocate away from the study site area in the next 1 year and 4 months
Current sexual partner is known to be infected with HIV or Hepatitis B virus
History of cirrhosis documented by previous liver biopsy or liver imaging tests
Reports participating in any other research study involving drugs or medical devices within 60 days or less prior to Enrollment
Clinically significant and habitual non-therapeutic drug abuse, not including marijuana, as determined by Protocol Chair
At Screening or Enrollment, as determined by the Protocol Chair, any significant uncontrolled active or chronic cardiovascular, renal, liver (such as evidence of decompensated cirrhosis by ascites, encephalopathy, or variceal hemorrhage), hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder or infectious disease (other than Hepatitis C)
Has a high risk of preterm birth defined as a history of spontaneous preterm birth at less than 34 weeks of gestation or a shortened cervical length of less than 20 millimeters
Has any of the following laboratory abnormalities at Screening:
Aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 10 times the upper limited of normal
Hemoglobin less than 9 g/dL
Platelet count less than 90,000 per mm3
International normalized ratio (INR) > 1.5
Creatinine greater than 1.4
Medical history of cirrhosis
Has any other condition that, in the opinion of the IoR/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives.